$26.75
2.29% yesterday
Nasdaq, May 20, 10:10 pm CET
ISIN
US6951271005
Symbol
PCRX

Pacira Pharmaceuticals, Inc. Stock price

$26.75
+0.85 3.28% 1M
+9.72 57.08% 6M
+7.91 41.99% YTD
-3.86 12.61% 1Y
-36.84 57.93% 3Y
-19.35 41.97% 5Y
-51.29 65.72% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.60 2.29%
ISIN
US6951271005
Symbol
PCRX
Sector
Industry

Key metrics

Market capitalization $1.24b
Enterprise Value $1.38b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 8.67
EV/Sales (TTM) EV/Sales 1.97
P/S ratio (TTM) P/S ratio 1.76
P/B ratio (TTM) P/B ratio 1.55
Revenue growth (TTM) Revenue growth 3.08%
Revenue (TTM) Revenue $702.77m
EBIT (operating result TTM) EBIT $90.64m
Free Cash Flow (TTM) Free Cash Flow $159.40m
Cash position $493.63m
EPS (TTM) EPS $-2.29
P/E forward 18.61
P/S forward 1.66
EV/Sales forward 1.86
Short interest 18.81%
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

3x Buy
43%
3x Hold
43%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
43%
Hold
43%
Sell
14%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
703 703
3% 3%
100%
- Direct Costs 215 215
11% 11%
31%
488 488
11% 11%
69%
- Selling and Administrative Expenses 227 227
16% 16%
32%
- Research and Development Expense 89 89
15% 15%
13%
172 172
3% 3%
24%
- Depreciation and Amortization 82 82
10% 10%
12%
EBIT (Operating Income) EBIT 91 91
3% 3%
13%
Net Profit -104 -104
247% 247%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
Neutral
PRNewsWire
8 days ago
SAN DIEGO , May 13, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX). Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation...
Neutral
Seeking Alpha
12 days ago
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Jonathan Slonin - Chief Medical Officer Shawn Cross - Chief Financial Officer Brendan Teehan - Chief Commercial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Gary Nachman - Ray...
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 790
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today